Startups

How Pipeline Organics Aims to Cut Wastewater Treatment Costs

Led by co-founders Andrew Raslan and Keyvan Jodeiri, Pipeline Organics is developing microbial fuel cells to help food and beverage manufacturers treat wastewater and recover energy as electricity.

Updated

November 16, 2026 12:32 PM

Concept visualisation of Pipeline Organics’ planned TankArc wastewater treatment and energy recovery system at a brewery. IMAGE: PIPELINE ORGANICS

A glass of beer or a bottle of soft drink leaves plenty behind before it reaches the shelf. Producing it requires water and electricity, then creates wastewater that manufacturers must pay to treat. For breweries and other food and beverage manufacturers working with tight margins, those bills can leave less money for new equipment, products and people.  

Pipeline Organics, led by Andrew Raslan (commercial) and Dr Keyvan Jodeiri (technology), sees a resource in that waste. The Nottingham-based cleantech startup, Pipeline Organics, is developing microbial fuel cells that treat food and beverage wastewater while generating electricity. The aim is to help factories lower their operating costs by recovering value from a stream they already produce every day.

Founded in August 2021, Pipeline Organics grew out of the University of Nottingham’s Young Entrepreneurs Scheme, YES20. The founding team won its Engineering, Energy and Environment stream before establishing the company. Andrew, now CEO, brought a background in molecular microbiology and antimicrobial research, later moving into project management and commercialization.

Co-founder and chief scientific officer Keyvan Jodeiri brought a different piece of the puzzle. His research explored biofuel cells that could use sugars in blood to generate electricity for medical implants. The team began asking whether related principles could work outside the body, using organic material in industrial wastewater as fuel. Turning that idea into a business meant finding an application where the environmental benefits came with a clear financial incentive.

Food and beverage manufacturing offered that opportunity. Breweries and other food and beverage manufacturers produce wastewater rich in biodegradable organic material such as leftover carbs and fats or dead proteins, making it suitable food for microorganisms. Treating it at the factory also gives the company a more predictable waste stream than the mixture arriving at a general sewage treatment plant.

“What is filthy for you as a manufacturer is food for the bacteria,” Andrew explains.

‍

Illustration of Pipeline Organics’ planned system, using microbial fuel cells to treat industrial wastewater and generate electricity. IMAGE: PIPELINE ORGANICS

‍

The company’s system, TankArc, contains reactors with specially designed, 3D-printed lattices. Microorganisms growing on the anode break down organic material in wastewater, releasing electrons that electrodes capture as electrical current. This reduces the organic pollution load while recovering some of its energy. Reactors can be grouped into racks or, eventually, containers equipped with plumbing, batteries and controls to serve different factory sizes.

Andrew describes the system as being designed to become self-powering, provided its electricity output scales as expected, with surplus energy available for use on site. At the moment, replacing a brewery’s entire electricity supply is beyond the immediate promise, Andrew admits. The more practical proposition is reducing the amount of power a manufacturer needs to buy through site efficiency upgrades, while cutting its wastewater treatment burden.

The treated wastewater would then go into the sewer for further treatment. Since it contains fewer pollutants, manufacturers could pay less in treatment charges or, in some cases, avoid them altogether. Pipeline Organics is also exploring ways to take the process further by working with partners to make water reuse possible. This could allow manufacturers to reuse the treated water for tasks that do not require high-purity water, such as post-production washing, which accounts for a large share of fresh-water use in the industry.

Much of TankArc’s engineering sits in the lattice itself. It needs sufficient surface area for the biological process while allowing wastewater to flow through without clogging. Different waste streams require different designs. Pipeline Organics combines engineering calculations with proprietary AI-assisted algorithms to adapt the geometry for applications such as beer, wine or fruit juice production.

‍

5-litre microbial fuel cell developed by Pipeline Organics. IMAGE: PIPELINE ORGANICS

‍

Andrew sees this design process as a competitive advantage. Once the geometry has been developed, components can be manufactured from the resulting 3D models. The difficult part is knowing how to design a cell that performs in a particular environment.

The company is competing with established wastewater treatment and energy recovery methods. Anaerobic digestion, for example, produces biogas that can subsequently generate heat and electricity. Pipeline Organics is pursuing direct electricity recovery through compact, modular equipment. Its suitability will depend on the site, the wastewater and the savings it can deliver.  

Early brewery trials have helped the team test those assumptions. At Little Ox Brewery, Pipeline Organics used a compact four-reactor system with real wastewater to assess compatibility and electrical output. The trial also provided practical lessons about monitoring, handling and operating equipment around a working production site. The company is working with Castle Rock Brewery in Nottingham as another development partner and have achieved onsite results that are close to commercial readiness.  

These demonstrations represent an early step towards industrial deployment. During our interview, Andrew said Pipeline Organics had begun selling paid feasibility pilots that measure performance using customers’ wastewater under actual operating conditions. Larger reactor racks would be at the next stage, followed by containerised systems for facilities producing much greater volumes of effluent. They expect to deploy full-scale containers in 2027.

Scaling brings another set of challenges. The team is developing repeatable methods for producing conductive electrodes, maintaining wastewater flow and assembling larger systems. Reducing manufacturing costs while maintaining treatment performance is a central part of this work.

‍

Pipeline Organics’ current benchtop prototype of its microbial fuel cell system. IMAGE: PIPELINE ORGANICS

‍

There will also be useful discoveries along the way: Chief Scientific Officer Keyvan says longer-term ambitions include developing the technology for wastewater sensing and exploring how recovered electricity could support electrochemical production of higher-value chemicals. These could open additional applications for the platform, while the immediate priority remains manufacturing and scaling the wastewater treatment system.

The proposed leasing model reflects the focus on customer economics. Manufacturers would rent equipment rather than purchase it upfront, retaining part of the savings after paying Pipeline Organics. Making that arrangement attractive requires dependable treatment, manageable maintenance and savings that hold up over time.  

Andrew’s and Keyvan’s longer-term vision includes a wider portfolio of environmental technologies. For now, the next test is closer to the brewery floor: can the company turn promising small reactors into equipment food and beverage manufacturers can rely on?

“One man’s waste is another man’s raw material if you’re smart about it,” Andrew says. Pipeline Organics is building its business around that possibility, starting with the water left behind by a drink.

Keep Reading

Operations & Scale

Cornerstone Robotics Expands European Push After Securing CE Approval for Surgical Robot System

The CE approval opens Europe for Cornerstone Robotics as the company expands its global surgical robotics business

Updated

August 10, 2026 5:56 PM

A tray of surgical tools. PHOTO: UNSPLASH

As surgical robotics companies expand beyond domestic markets, regulatory approvals are becoming a critical part of global growth. Companies are no longer competing only on hardware and clinical performance. They are also competing on their ability to enter tightly regulated healthcare systems and build long-term hospital partnerships.

Hong Kong-based Cornerstone Robotics is now moving further into that phase of expansion after its Sentire Endoscopic Surgical System received CE Mark certification under the European Union’s Medical Device Regulation framework.

The approval allows the company to commercialize the system across European markets for minimally invasive procedures in general surgery, gynecology, thoracic surgery and urology. For surgical robotics companies, regulatory approvals often represent more than product validation. They also determine market access, hospital adoption opportunities and long-term commercial scale.

Cornerstone Robotics has already been building clinical operations in the UK ahead of the approval. Since 2025, the company has worked with Portsmouth Hospitals University NHS Trust on clinical investigations involving the Sentire Surgical System. According to the company, the system has been used across procedures involving urology, gynecology and gastrointestinal surgery. The company says the clinical investigation helped generate real-world data to support physician training, research and future adoption efforts.

Alongside the regulatory approval, Cornerstone Robotics is also expanding its local operations in Europe. The company established a UK subsidiary in 2025 and has been developing training, clinical support and after-sales service capabilities for hospitals using the system.

That operational buildout reflects a larger challenge inside surgical robotics. Hospitals adopting robotic systems often require ongoing clinical training, technical support and workflow integration alongside the hardware itself.

Cornerstone Robotics says its strategy centers around vertically integrated development across engineering, software, imaging and robotics systems. The company argues that this structure gives it greater control over product development, supply chain management and long-term operational stability.

Professor Samuel Au, Founder and CEO of Cornerstone Robotics, said: "Receiving CE Certification marks a major milestone in Cornerstone Robotics' evolution from a technology innovator to a global clinical solutions provider. From our first clinical investigation in Portsmouth, UK, to achieving European regulatory approval, each step of the journey reflects our commitment to proprietary innovation, product excellence, and clinical value. Looking ahead, we will continue expanding into key global markets and partnering with leading medical institutions to bring high-quality surgical robotic solutions to more physicians and patients worldwide."

The CE approval also comes several months after the company completed an oversubscribed financing round of approximately US$200 million in November 2025.

The funding and regulatory expansion together signal how surgical robotics companies are increasingly entering a more commercially focused stage of growth. Beyond research and development, companies are now investing more heavily in regulatory approvals, hospital partnerships, physician training and international operational infrastructure as competition expands across global healthcare markets.

‍